Abstract: The present invention relates to methods of modulating an immune response mediated by a PD-1 signaling pathway and of treating a cancer or an infectious disease. A subject is administered a compound(s) or a pharmaceutically acceptable salt or pharmaceutically acceptable composition thereof of formula (I) In the ring Q is S or O. R1 substituents are an optionally substituted side chain of the amino acid Ser or Thr and R3 substituents are a side chain of the amino acids Asn, Asp, Gln, or Glu. R2 is hydrogen or —CO-Aaa and Aaa is Thr or Ser with a free, amidated or esterified C-terminus. R4 and R5 are independently hydrogen or absent. R6 is hydrogen, alkyl or acyl.

Abstract: Examples disclosed herein relate to a grace link state advertisement (LSA) from a virtual stack device. In an example, a first member network device of a virtual stack device may an input from a Multi-Active Detection (MAD) device. The virtual stack device may be a logical network device comprising the first member network device and a second member network device. Based on the input from the MAD device, the first member network device may determine whether a grace link state advertisement (LSA) is to be sent to a neighbor Open Shortest Path First (OSPF) enabled router by the first member network device, wherein the neighbor OSPF enabled router is an OSPF neighbor to the virtual stack device.

Abstract: The present invention relates to synthetic methods for 1,2,4-oxadiazole compounds. The general synthetic scheme is: R1 represents ?CH2OtBu or ?CH(CH3)OtBu, R3 represents ?CH2C(O)NHCPh3, ?CH2CH2C(O)NHCPh3, ?CH2C(O)OtBu, or ?CH2CH2C(O)OtBu, and Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with tbutyl; the base is triethylamine; and the solvent is tetrahydrofuran.

Abstract: The present invention relates to synthetic methods for 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds. The general synthetic scheme is: R1 substituents are —CH2OH, —CH(CH3)OH, —CH2Ph, —CH3, or —CH2C(O)NH2 optionally substituted with alkyl or aralkyl. R3 substituents are —CH2OH, —CH3, —CH2CH2C(O)OH, —CH2CH2C(O)NH2, —CH2C(O)NH2, or —CH2C(O)OH, wherein the carboxylic acids and amides are optionally substituted with alkyl or aralkyl.

Abstract: Methods of making a compound according to the following scheme: wherein: R1 is a side chain of an amino acid residue selected from Ala, Ser, Thr and Leu; R2 is a side chain of an amino acid residue selected from Asp, Glu, Gln and Asn; [Aaa] is an amino acid residue selected from Ser, Asp, Ala, Ile, Phe, Trp, Lys, Glu and Thr; R3 is hydrogen or alkyl; Each of R4 and R4? independently is hydrogen or alkyl; Both Ra and Ra? are hydrogen; or together are an oxo(?O) group; Both Rb and Rb? are hydrogen; or together are an oxo (?O) group; L is X is CH2, O or S; R5 is hydrogen or alkyl; m is an integer from 1 to 3; and n is an integer from 2 to 20.

Abstract: Examples disclosed herein relate to reducing flooding of route updates of a dynamic routing protocol. In an example, number of route updates received by a router from each neighbor router may be determined, wherein the router may be present in a network using a dynamic routing protocol. Each neighbor router may be classified into one of a plurality of groups of neighbor routers in such a manner that number of route updates originating from each group of neighbor routers is approximately same. A first route update interval may be determined for each group of neighbor routers for sending a respective first set of future route updates therefrom to the router. The respective first route update interval for sending the respective first set of future route updates may be notified to the respective member routers of each group of neighbor routers.

Abstract: The present invention relates to synthetic methods for 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds. The general synthetic scheme is: R1 substituents are —CH2OH, —CH(CH3)OH, —CH2Ph, —CH3, or —CH2C(O)NH2 optionally substituted with alkyl or aralkyl. R3 substituents are —CH2OH, —CH3, —CH2CH2C(O)OH, —CH2CH2C(O)NH2, —CH2C(O)NH2, or —CH2C(O)OH, wherein the carboxylic acids and amides are optionally substituted with alkyl or aralkyl.

Abstract: The present invention relates to synthetic methods for 1,2,4-oxadiazole compounds. The general synthetic scheme is: R1 substituents generally are optionally substituted methanol or ethanol moieties, R3 substituents generally are optionally substituted acetic or propanoic acids or their amides and Aaa is Thr or Ser which has a free, amidated or esterified C-terminus.

Abstract: The present invention relates to 3-substituted-1,2,4-oxadiazole and thiadiazole compounds of formula (I) or formula (II) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Abstract: The present invention relates to 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Abstract: The present invention relates to 3-substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Abstract: The present invention relates to cyclic compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.

Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract: The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract: The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract: The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract: The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.